* Ultralife Corp ULBI.OQ ULBI.O is expected to report
results on July 29.
* The Newark New York, New York-based company is expected to
report revenue of $29 million, according to the estimate from
one analyst, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Ultralife Corp is for
earnings of 9 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Ultralife Corp
is $12, about 30.7% above its last closing price of $8.32.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 0.06 0.06 0.04 Missed -33.3
This summary was machine generated July 27 at 13:05 GMT. All
figures in US dollars unless otherwise stated